Dicerna Pharmaceuticals, Inc. (DRNA)
(Delayed Data from NSDQ)
$13.09 USD
+0.43 (3.40%)
Updated May 3, 2019 04:00 PM ET
After-Market: $13.09 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[DRNA]
Reports for Purchase
Showing records 1 - 20 ( 60 total )
Industry: Medical - Biomedical and Genetics
Novo Nordisk Acquisition Closes; Terminating Coverage
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
Novo Nordisk to Acquire Dicerna at 80% Premium; Downgrade to Neutral; Raise PT to $38.25
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
3Q Recap; Moving Closer to Nedosiran''s NDA for PH1; Announcement of 1st Extrahepatic Program in Early 2022; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
Effect Size of Nedosiran in PH3 Patients Insufficient, As Expected; NDA for PH1 This Quarter; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
Dicerna''s Second Wholly-Owned Asset, DCR-AUD, Enters the Clinic; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
2Q Recap: In a Strategic Pivot, Dicerna to License Global Commercial Rights to Nedosiran; PT to $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
PHYOX2 a Clear Win in PH1, Validating GalXC RNAi Platform, Despite Miss in PH2 Cohort; Reduce PT to $38
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
Belcesiran Demonstrates Profound Single-Dose AAT Reductions in Phase 1 Interim Analysis; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
A Star Is Born and it Appears Set to SHINE; Raise PT to $42
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
New RNAi Candidate Targeting Lp(a) to Enter the Clinic Under Lilly Collaboration; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
New NASH Candidate Underscores Ever-Expanding Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
1Q21 Recap; Approaching Two Pivotal Nedosiran Data Readouts for All PH Subtypes in Coming Months; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
Roche Initiates Phase 2 HBV Trial of Multiple Combination Regimens; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
4Q20 Recap; Several Catalysts Across Multiple Programs in 2021; Alcohol Use Disorder Program Unveiled; Raise PT to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
Nedosiran NDA Submission in 3Q21 Remains on Target With First Patient Dosing in PHYOX4; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
First Major Milestone Achieved in Novo Nordisk Collaboration With First Candidate Selected
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
PHYOX2 Pivotal Trial of Nedosiran Completes Enrollment; Top-line Data On Target for Mid-2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
IND Accepted for LY3561774; Phase 1 Initiation Expected by Year-End; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Industry: Medical - Biomedical and Genetics
Unveiling Five-Year Vision as a Best-in-Class RNAi Developer and Growing FIPCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E